QID 91784

Date Published: 2021-07-07

QID 91784: IBM Integration Bus and IBM App Connect Enterprise Node.js Multiple Vulnerabilities (6467639)

IBM App Connect Enterprise combines the existing, industry-trusted technologies of IBM Integration Bus with IBM App Connect Professional and with new cloud-native technologies, to deliver a platform that supports the full breadth of integration needs across a modern digital enterprise.
IBM Integration Bus (formerly known ad IBM WebSphere Message Broker) is IBM's integration broker from the WebSphere product family that allows business information to flow between disparate applications across multiple hardware and software platforms.

Affected Products and Versions:
IBM Integration Bus V10.0.0 - V10.0.0.23
IBM App connect Enterprise V11.0.0.0 - V11.0.0.12

QID Detection Logic (Authenticated):
Operating System: Windows
The QID checks if a vulnerable version of IBM Integration Bus and IBM App Connect Enterprise is installed on the system.

A remote attacker could exploit this vulnerability to cause the TLS server to crash i.e, denial of service.

  • CVSS V3 rated as High - 7.4 severity.
  • CVSS V2 rated as Medium - 5.8 severity.
    • Solution
    Users are advised to follow the patching procedure provided by IBM. Further information can be obtained from IBM Security Bulletin (6467639)
    Vendor References

    CVEs related to QID 91784

    CVE-2021-3449 | CVE-2021-3450 |
    Software Advisories
    Advisory ID Software Component Link
    6467639 URL Logo www.ibm.com/support/pages/node/6467639
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].